Parnax Lab Ltd Q2 FY26 – From Cough Syrup to Corporate Shake-Up: How a ₹131 Cr Pharma Underdog Is Mixing Profits, Promoters, and Paracetamol
1. At a Glance
Parnax Lab Ltd (PLL), the unsung cousin at the pharma family reunion, has been quietly compounding cough syrup profits while the big boys (Sun, Cipla, and Dr. Reddy’s) hogged all the headlines. With a market cap of just ₹131 crore and a share price lounging around ₹114, this Naxpar Group entity is the classic underdog story—if the underdog also moonlights as a contract manufacturer for Dabur, Cipla, and Himalaya.
The latest quarter ending September 2025 showed sales of ₹62.6 crore and PAT of ₹3.62 crore, clocking a YoY revenue growth of 29.4% and a profit uptick of 6.45%. Not bad for a company that once looked like it was mixing losses instead of syrups. With a P/E of 11.9, ROE of 15.1%, and ROCE of 14%, Parnax is sipping from a beaker labeled “respectable returns.”
And while the stock is still 32% down over the last year, the numbers say it’s not coughing anymore—it’s breathing profitably. But can a Silvassa-based lab really play in the big league with Sun Pharma and Zydus? Let’s pop the lid on this formulation.
2. Introduction
Pharma stocks in India are like Bollywood families—some have dynasties, some have drama, and a few like Parnax Lab have both. Born in 1985 (when Doordarshan ruled the world and “antibiotic” was still a complicated word), the company began as a manufacturer of pharmaceutical formulations and slowly evolved into a contract manufacturing powerhouse.
Today, it’s the go-to lab for big brands who prefer outsourcing their headaches—literally. From liquid orals and ointments to capsules and herbal creams, Parnax has managed to become the behind-the-scenes producer for multiple FMCG and pharma giants. Yet, with all that pedigree, it remains a microcap in valuation terms—like a talented background dancer still waiting for its solo number.
The financials show consistency, the client list screams credibility, and the promoter holding of 72.3% implies they’re not just here to mix formulations—they’re committed to this concoction. The catch? No dividends, low liquidity, and a habit of quietly diluting shares through preferential allotments (remember those 16.7 lakh shares converted in July 2022?).
So, what’s the formula behind this low-key yet resilient pharma warrior? Time to dissect.
3. Business Model – WTF Do They Even Do?
Imagine a chef who doesn’t own a restaurant but cooks for everyone else’s Michelin-star kitchens. That’s Parnax Lab in a nutshell. It manufactures pharmaceutical and cosmetic formulations for giants like Himalaya, L’Oréal, Cipla, Dabur, and Wockhardt. Essentially, it’s the contract manufacturing arm your favorite health brand secretly depends on.
Their Silvassa plant produces everything from cough syrups and antacids to fairness creams and herbal balms. The product range is wild—covering pharmaceuticals, cosmetics, herbal, and nutraceutical segments. So yes, they can make your cough syrup, your anti-dandruff gel, your UV cream, and your herbal balm, all under one roof.
With production capacities like 60 KL/day of liquid orals and 20 tons/day of creams, this lab’s manufacturing muscle is impressive for its scale.
Their service suite is equally pharma-corporate—regulatory approvals, CRAMS (Contract Research and Manufacturing Services), NDDS tie-ups, and in/out licensing. In short, they do all the boring but critical stuff that keeps your medicine bottles full and your pharmacy shelves organized.
And their export map stretches from Nigeria to Kazakhstan, with plans to enter South-East Asia and Latin America. A small Indian lab dreaming global—now that’s a formulation worth watching.
4. Financials Overview
Let’s break down the numbers from the latest Quarterly Results (Q2 FY26):
Source table
Metric
Sep 2025 (Latest Qtr)
Sep 2024 (YoY Qtr)
Jun 2025 (Prev Qtr)
YoY %
QoQ %
Revenue (₹ Cr)
62.6
48.36
53.38
29.4%
17.3%
EBITDA (₹ Cr)
8.08
7.24
7.44
11.6%
8.6%
PAT (₹ Cr)
3.62
3.42
3.28
5.8%
10.4%
EPS (₹)
3.16
2.97
2.85
6.4%
10.9%
Commentary: Parnax’s quarterly numbers are like a slow-release capsule—steady, effective, and non-volatile. The YoY revenue growth of 29.4% is a solid comeback in a sector dominated by price wars and regulatory pressures. EBITDA margins hover around 13%, stable as a seasoned pharmacist’s pulse. EPS has risen to ₹3.16, which annualized gives an EPS of ~₹12.6—making that P/E of 11.9 look even cheaper.
The numbers say “healthy.” The stock price says “ignored.” A classic desi mismatch.
5. Valuation Discussion – Fair Value Range
Method 1: P/E Based Industry P/E = 30.6 Company P/E = 11.9 Annualized EPS = ₹12.6 → Fair Value Range (10x–20x) = ₹126 – ₹252
Method 2: EV/EBITDA EV = ₹198 Cr; EBITDA (TTM) = ₹27 Cr EV/EBITDA = 7.33x Fair EV/EBITDA (sector 10x–14x) = ₹270–₹378 Cr → Market Cap Range ₹200–₹300 Cr → Share Value Range ₹175–₹260
Method 3: DCF (simplified) Assuming cash flow growth 10% for 5 years and 10% discount → Fair Range ₹160–₹220
Fair Value Educational Range: ₹160 – ₹250 per share
Disclaimer: This fair value range is for educational purposes only and not investment advice. Even the lab couldn’t prescribe otherwise.
